Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Intelgenx Technologies Corp IGXT


Primary Symbol: T.IGX

Healthcare
IntelGenx Technologies Corp. is a Canada-based drug delivery company. The Company provides single-site, end-to-end contract development and manufacturing services of oral thin film and transdermal drug products for the pharmaceutical and animal health markets, spanning the entire drug development and commercial product cycle. The Company’s film technologies, including VersaFilm, DisinteQ... see more

Recent & Breaking News (TSX:IGX)

IntelGenx Announces Notice of Grant of European Patent Covering  Rizaport® VersaFilm™

GlobeNewswire June 19, 2018

IntelGenx Announces Issuance of Shares in Payment of Interest on Outstanding Debentures

GlobeNewswire June 14, 2018

IntelGenx Grants Stock Options

GlobeNewswire June 11, 2018

Article in Alzheimer's & Dementia Points to an Additional Unmet Medical Need Targeted by IntelGenx’ Montelukast VersaFilm™

GlobeNewswire June 6, 2018

Performance and Restricted Share Unit Plan Approved by IntelGenx Technologies Corp. Shareholders

GlobeNewswire May 15, 2018

IntelGenx Announces Settlement of Suboxone® Patent Litigation

GlobeNewswire May 14, 2018

IntelGenx Reports First Quarter 2018 Financial Results

GlobeNewswire May 10, 2018

IntelGenx Closes Private Placement Financing

GlobeNewswire May 8, 2018

IntelGenx to Report First Quarter 2018 Financial Results on May 10, 2018 – Conference Call to Follow

GlobeNewswire May 3, 2018

IntelGenx Announces Proposed Private Placement

GlobeNewswire May 1, 2018

IntelGenx Reports Fourth Quarter and Full-Year 2017 Financial Results

GlobeNewswire March 29, 2018

Intelgenx Technologies Corp. to Host Earnings Call

Accesswire March 29, 2018

IntelGenx Announces Update on Private Placement and Proposed LaboVal Acquisition

GlobeNewswire March 27, 2018

IntelGenx to Report Fourth Quarter and Full-Year 2017 Financial Results on March 29, 2018 – Conference Call to Follow

GlobeNewswire March 23, 2018

IntelGenx Announces Proposed Private Placement

GlobeNewswire March 20, 2018

IntelGenx Announces Proposed Acquisition of Laboval

GlobeNewswire March 19, 2018

IntelGenx Clarifies Recent Preliminary 2018 Proxy Statement Filing

GlobeNewswire March 12, 2018

IntelGenx Mourns the Passing of long term Director Ian Troup

GlobeNewswire January 26, 2018

IntelGenx Initiates Phase 2A Montelukast Versafilm™ Clinical Trial in Alzheimer’s Patients

GlobeNewswire January 24, 2018

IntelGenx To Present at Biotech Showcase(TM) 2018

GlobeNewswire January 4, 2018